In a specific strain of rats with diabetes, daily doses of the drug canagliflozin for one week reduce high blood sugar after meals and improve the liver's ability to process glucose by moving an...

We analyzed one study on Zucker diabetic fatty rats and found that daily doses of canagliflozin for one week were associated with lower blood sugar after meals and improved how the liver handles glucose. The study suggests this effect may be linked to glucokinase — an enzyme that helps liver cells take in and store glucose as glycogen — moving to the right location inside the cells. This shift was also tied to increased fat use during fasting, without changes to insulin-related pathways [1]. What we’ve found so far is limited to a single assertion based on one animal study. There is no evidence in our review that contradicts this finding, but we also have no additional studies to confirm whether this mechanism applies beyond this specific rat strain or under different conditions. The study does not show whether these changes occur in humans, or if they last beyond one week of treatment. We also cannot say whether glucokinase translocation is the main reason for the observed effects, or if other factors played a role. The evidence we’ve reviewed leans toward the idea that canagliflozin may help normalize post-meal blood sugar and improve glucose processing in this type of diabetic rat by influencing where glucokinase is located in liver cells. But without more studies — especially in humans — we cannot say how this translates to real-world use. For now, this finding remains a specific observation in one animal model. It may help guide future research, but it does not yet provide clear guidance for human treatment decisions.